Chardan Capital Reiterates “Buy” Rating for Alto Neuroscience (NYSE:ANRO)

Alto Neuroscience (NYSE:ANRO)‘s stock had its “buy” rating reissued by stock analysts at Chardan Capital in a report issued on Tuesday,Benzinga reports. They presently have a $30.00 price target on the stock. Chardan Capital’s price target would suggest a potential upside of 23.63% from the stock’s current price.

A number of other research firms have also recently weighed in on ANRO. BTIG Research upped their price target on Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Jefferies Financial Group reiterated a “buy” rating and set a $35.00 price objective on shares of Alto Neuroscience in a research note on Monday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $31.17.

Alto Neuroscience Trading Up 9.0%

Shares of ANRO opened at $24.27 on Tuesday. Alto Neuroscience has a 12 month low of $1.60 and a 12 month high of $25.13. The stock’s 50-day moving average is $17.96 and its two-hundred day moving average is $13.22. The company has a debt-to-equity ratio of 0.20, a current ratio of 15.42 and a quick ratio of 15.42. The stock has a market cap of $753.91 million, a PE ratio of -10.60 and a beta of 2.51.

Alto Neuroscience (NYSE:ANRO) last posted its earnings results on Thursday, March 19th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11. Equities analysts forecast that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Bank of Montreal Can acquired a new stake in shares of Alto Neuroscience in the 2nd quarter valued at about $25,000. AlphaCore Capital LLC grew its stake in Alto Neuroscience by 100.0% in the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after purchasing an additional 10,000 shares in the last quarter. AQR Capital Management LLC acquired a new position in Alto Neuroscience in the first quarter worth about $52,000. Torren Management LLC bought a new stake in Alto Neuroscience in the fourth quarter valued at about $62,000. Finally, Invesco Ltd. bought a new stake in Alto Neuroscience in the first quarter valued at about $67,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.